Suppr超能文献

接受卡介苗治疗的膀胱癌患者免疫细胞模式的时间动态变化。

Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guérin therapy.

作者信息

Lu Jiang-Li, Ye Yun-Lin, Zheng Dan-Dan, Shi Xin-Yu, Hu Li-Ling, Yuan Xiao-Yi, Cai Tao-Nong, Meng Kun, Wen Neng-Qiao, Li Yu-Ying, Wang Ding-Kang, Shi Fu-Jin, Liu Dan-Ya, He Qing-Yu, Qin Zi-Ke, Zhang Chris Zhiyi, Cao Yun

机构信息

MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou, China.

Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Br J Cancer. 2024 Dec;131(12):1901-1912. doi: 10.1038/s41416-024-02883-5. Epub 2024 Oct 31.

Abstract

BACKGROUND

Bacillus Calmette-Guérin (BCG) is capable of enhancing the infiltration of immune cells into the tumour. However the temporal dynamics of immune cell patterns in patients receiving BCG instillation remains unclear.

METHODS

Ninety-six patients who underwent intravesical BCG therapy, comprising 46 responders and 50 non-responders, were retrospectively enroled to explore the evolving immune landscape. This study involved a detailed examination of sequential samples collected before, during, and after BCG treatment to assess BCG's influence on the immune microenvironment, employing techniques such as immunohistochemistry, fluorescent multiplex immunohistochemistry, and mass spectrometry techniques.

RESULTS

Our study found that initial BCG instillation leads to enhanced immune cell infiltration, correlating with treatment efficacy, with responders exhibiting more pronounced increases. Non-responders experience a rise in immune cell infiltration and PD-L1 expression during the first instillation, which returns to baseline after treatment. In non-responders, BCG re-challenge fail to further increase immune cell infiltration into the tumour or improve patient outcomes. Strikingly, proteomics data revealed that GBP1 expression was induced by BCG treatment in non-responders.

CONCLUSIONS

Our findings demonstrated the induction of tumour PD-L1 expression by BCG in non-responders, and therefore provide insights for the combination of BCG and anti-PD1/anti-PD-L1 therapy.

摘要

背景

卡介苗(BCG)能够增强免疫细胞向肿瘤内的浸润。然而,接受卡介苗灌注治疗的患者体内免疫细胞模式的时间动态变化仍不清楚。

方法

回顾性纳入96例接受膀胱内卡介苗治疗的患者,其中46例有反应者和50例无反应者,以探索不断演变的免疫格局。本研究详细检查了在卡介苗治疗前、治疗期间和治疗后采集的系列样本,采用免疫组织化学、荧光多重免疫组织化学和质谱技术等评估卡介苗对免疫微环境的影响。

结果

我们的研究发现,初次卡介苗灌注导致免疫细胞浸润增强,这与治疗效果相关,有反应者的增加更为明显。无反应者在首次灌注期间免疫细胞浸润和PD-L1表达增加,治疗后恢复至基线水平。在无反应者中,再次卡介苗刺激未能进一步增加免疫细胞向肿瘤内的浸润或改善患者预后。引人注目的是,蛋白质组学数据显示,无反应者经卡介苗治疗后GBP1表达被诱导。

结论

我们的研究结果证明了卡介苗在无反应者中诱导肿瘤PD-L1表达,因此为卡介苗与抗PD1/抗PD-L1治疗联合应用提供了见解。

相似文献

5
Intravesical gemcitabine for non-muscle invasive bladder cancer.膀胱内注射吉西他滨治疗非肌层浸润性膀胱癌。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2.

引用本文的文献

本文引用的文献

10
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.膀胱癌对卡介苗临床反应的免疫学特征。
Front Immunol. 2021 Jan 29;11:615091. doi: 10.3389/fimmu.2020.615091. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验